Peps
What is FOXO4-DRI?
FOXO4-DRI is an experimental peptide designed to disrupt an interaction involved in senescent-cell survival. Its widely discussed aging findings come from cell and mouse experiments.
Biological role or research focus
Senescent-cell biology.
Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.
Role reference: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. · 2017 ↗
Names you may encounter
FOXO4 D-retro-inverso peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental D-retro-inverso senolytic peptide
- Research focus
- Senescent-cell biology
- Featured evidence
- Animal and cell study
- Source check
- October 4, 2026
Biology & proposed mechanism
The investigators targeted the FOXO4–p53 interaction to favor apoptosis in senescent cells. Selectivity observed in experimental systems does not establish selective clearance or safety in a person.
Research context & identity
The featured publication examines senescence and aging models, including chemotherapy-associated injury. It is not a human longevity or rejuvenation trial.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal and cell study · 2017
FOXO4–p53 interference in senescent cells
What did this publication test, and what did it find?
- Population / model
- Senescent cells and naturally aged or accelerated-aging mice.
- Study design
- Mechanistic cell experiments and mouse interventions assessing senescence-associated changes and physical or organ-function measures.
- Main finding
- The study reported senescent-cell apoptosis and improvements in selected mouse measures, including fitness, fur density, and kidney function.
- Limits & context
- Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. ↗
Circulation · 2023 Feb 21 · Journal Article, Research Support, Non-U.S. Gov't
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. ↗
Nature communications · 2025 Jul 1 · Journal Article
Read available full text ↗
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. ↗
Communications biology · 2025 Feb 24 · Journal Article
Read available full text ↗
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. ↗
Frontiers in bioengineering and biotechnology · 2025 · Journal Article
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Eliminating senescent cells can affect tissues differently. This preclinical report cannot define a human risk profile or verify a supplier’s material.
Evidence boundaries
Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
1 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Yaşlanmayı Durduran Hücre Silahı: FOXO4-DRI Nedir? ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Has this study proved human rejuvenation?
- What material, population, and route were actually studied?
- Mouse aging measures are not proof of increased human lifespan, improved healthspan, or safe preventive use.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Has this study proved human rejuvenation?
No. Its cell and mouse results support a research hypothesis; they do not demonstrate a human longevity benefit.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.